NCT02822326View on ClinicalTrials.gov

Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Acute Leukemia
Interventions
BIOLOGICAL

CD19-CAR-T2 Cells

Trial Locations (1)

510080

RECRUITING

Guangdong General Hospital, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Chinese Academy of Sciences

OTHER_GOV

collaborator

Guangdong Zhaotai InVivo Biomedicine Co. Ltd.

OTHER

lead

Guangdong Provincial People's Hospital

OTHER

NCT02822326 - Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia | Biotech Hunter | Biotech Hunter